Point72 Asia Singapore Pte. Ltd. Purchases Shares of 850 HealthEquity, Inc. (NASDAQ:HQY)

Point72 Asia Singapore Pte. Ltd. acquired a new position in HealthEquity, Inc. (NASDAQ:HQY) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 850 shares of the company’s stock, valued at approximately $73,000.

Several other institutional investors and hedge funds have also recently modified their holdings of HQY. Rise Advisors LLC bought a new position in HealthEquity in the 1st quarter worth approximately $28,000. International Assets Investment Management LLC purchased a new position in HealthEquity during the second quarter valued at $35,000. YHB Investment Advisors Inc. purchased a new position in HealthEquity during the first quarter valued at $40,000. Fidelis Capital Partners LLC purchased a new stake in HealthEquity in the 1st quarter worth $42,000. Finally, Parallel Advisors LLC lifted its stake in HealthEquity by 255.5% in the 4th quarter. Parallel Advisors LLC now owns 679 shares of the company’s stock worth $45,000 after purchasing an additional 488 shares in the last quarter. 99.55% of the stock is currently owned by institutional investors.

HealthEquity Trading Up 1.6 %

HQY opened at $79.93 on Monday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 4.10 and a current ratio of 4.10. The stock’s 50 day moving average price is $76.29 and its 200-day moving average price is $79.21. HealthEquity, Inc. has a one year low of $61.81 and a one year high of $88.26. The stock has a market cap of $6.95 billion, a price-to-earnings ratio of 86.88, a P/E/G ratio of 1.25 and a beta of 0.52.

HealthEquity (NASDAQ:HQY) last announced its quarterly earnings data on Tuesday, September 3rd. The company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.50 by $0.16. HealthEquity had a return on equity of 9.01% and a net margin of 9.61%. The company had revenue of $299.93 million for the quarter, compared to the consensus estimate of $284.48 million. On average, equities analysts forecast that HealthEquity, Inc. will post 2.25 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on HQY shares. Deutsche Bank Aktiengesellschaft lifted their target price on HealthEquity from $102.00 to $103.00 and gave the stock a “buy” rating in a report on Wednesday, September 4th. Bank of America lowered their target price on HealthEquity from $105.00 to $100.00 and set a “buy” rating for the company in a research report on Wednesday, September 4th. Royal Bank of Canada restated an “outperform” rating and issued a $92.00 price target on shares of HealthEquity in a research report on Wednesday, September 4th. Robert W. Baird increased their price objective on shares of HealthEquity from $98.00 to $104.00 and gave the company an “outperform” rating in a research report on Tuesday, June 4th. Finally, KeyCorp boosted their target price on shares of HealthEquity from $95.00 to $100.00 and gave the stock an “overweight” rating in a report on Wednesday, June 5th. One research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $103.83.

Insider Transactions at HealthEquity

In other HealthEquity news, Vice Chairman Stephen Neeleman sold 35,000 shares of the business’s stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $79.86, for a total value of $2,795,100.00. Following the completion of the sale, the insider now directly owns 89,769 shares of the company’s stock, valued at approximately $7,168,952.34. The transaction was disclosed in a filing with the SEC, which is available through this link. In other news, Director Frank Corvino sold 7,705 shares of the stock in a transaction on Monday, July 8th. The stock was sold at an average price of $81.89, for a total transaction of $630,962.45. Following the transaction, the director now owns 6,070 shares of the company’s stock, valued at approximately $497,072.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Vice Chairman Stephen Neeleman sold 35,000 shares of HealthEquity stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $79.86, for a total value of $2,795,100.00. Following the completion of the sale, the insider now owns 89,769 shares of the company’s stock, valued at $7,168,952.34. The disclosure for this sale can be found here. Company insiders own 2.20% of the company’s stock.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.